A potent efficacy of pioglitazone on alcoholic and non-alcoholic fatty liver disease in type 2 diabetic mellitus

A potent efficacy of pioglitazone on alcoholic and non-alcoholic fatty liver disease in type 2 diabetic mellitus - A potent efficacy of pioglitazone on alcoholic and non-alcoholic fatty liver disease in type 2 diabetic mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046797

Enrollment

100

Registered

2022-02-01

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who had newly prescribed pioglitazone from October 2015 to September 2020

Exclusion criteria

Exclusion criteria: Patients who refused to participate in this study

Design outcomes

Primary

Measure	Time frame
The changes of liver enzymes such as AST, ALT and g-GTP in three months after the administration of pioglitazone	—

Secondary

Measure	Time frame
The changes of HbA1c and FIB-4 Index in three months after the administration of pioglitazone	—

Countries

Japan

Contacts

Public ContactMasahiro Asakawa

Tokyo Teishin Hospital Department of Endocrinology and Metabolism

m.asakawa@tth-japanpost.jp03-5214-7111

Outcome results